{"gene":"ABCB1","run_date":"2026-06-09T22:02:36","timeline":{"discoveries":[{"year":1989,"finding":"Gp170 (ABCB1/P-gp) functions as an ATP-dependent efflux pump in rat liver canalicular membrane vesicles, mediating unidirectional, temperature-dependent, osmotically sensitive, and saturable transport of daunomycin. ATP hydrolysis (not non-hydrolyzable analogues) is required, and transport is inhibited by cytotoxic drugs (vinblastine, vincristine, adriamycin) and verapamil/quinidine. Only inside-out vesicles (cytoplasmic face outward) support transport, establishing vectorial drug efflux into bile.","method":"ATP-dependent transport assay in canalicular membrane vesicles; antibody-induced affinity density perturbation to separate inside-out from right-side-out vesicles; inhibitor studies","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstituted transport assay with multiple orthogonal controls (non-hydrolyzable ATP analogues, inhibitors, osmotic sensitivity, inside-out vs right-side-out vesicles), replicated concept across labs","pmids":["2568355"],"is_preprint":false},{"year":1992,"finding":"Gp170 (ABCB1) in rat small intestinal brush border membrane vesicles (but not basolateral) functions as an ATP-dependent efflux pump transporting daunomycin from inside to outside. Non-hydrolyzable ATP analogues are ineffective. Everted intestine preparations confirm Gp170-mediated serosal-to-mucosal transport of rhodamine 123, inhibitable by Gp170 inhibitors, establishing P-gp as an intestinal barrier against hydrophobic xenobiotics.","method":"ATP-dependent transport assay in brush border membrane vesicles; everted intestine transport assay; inhibitor studies; Western blot with anti-Gp170 antibody","journal":"Gastroenterology","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstituted transport in native membrane vesicles with multiple controls, directional transport confirmed by two complementary experimental systems","pmids":["1347031"],"is_preprint":false},{"year":2005,"finding":"ABCB1/P-gp in human placenta is functionally active as an ATP-dependent efflux transporter: ATP-dependent uptake of [3H]vinblastine in placental vesicles is osmotically sensitive (indicating intravesicular accumulation) and inhibited by verapamil. The protein is expressed at high levels and localized to the syncytiotrophoblast, consistent with a fetal-protective barrier role.","method":"ATP-dependent vesicle transport assay with [3H]vinblastine; verapamil inhibition; Western blotting; immunohistochemistry","journal":"Drug metabolism and disposition","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstituted transport assay with osmotic sensitivity and pharmacological inhibition controls, single lab but multiple orthogonal methods","pmids":["15640379"],"is_preprint":false},{"year":2006,"finding":"In human and rat brain, P-gp (ABCB1) localizes to both luminal and abluminal membranes of capillary endothelial cells, as well as to adjacent pericytes and astrocytes. Subcellularly, P-gp is distributed in caveolae, cytoplasmic vesicles, Golgi complex, rough ER, and nuclear envelope, indicating sites of synthesis, glycosylation, and membrane trafficking. Bilateral membrane localization suggests P-gp regulates drug transport processes across the entire BBB.","method":"Immunogold cytochemistry at electron microscope level in situ in rat and human brain tissue","journal":"The journal of histochemistry and cytochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct subcellular localization by immunogold EM, single lab, two species examined","pmids":["16801529"],"is_preprint":false},{"year":2007,"finding":"The linker domain of human ABCB1 (approximately 90 amino acid region connecting the two halves) contains sequences that directly bind alpha- and beta-tubulins. Three polypeptide sequences (LDS617-627, LDS657-676, LDS693-705) interact with a ~57 kDa protein identified by N-terminal sequencing and anti-tubulin Western blot as alpha- and beta-tubulin, establishing a direct protein-protein interaction between ABCB1 and cytoskeletal components.","method":"Overlapping hexapeptide binding assay; protein purification; N-terminal amino acid sequencing; Western blot with anti-tubulin monoclonal antibodies","journal":"Biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — direct binding demonstrated by peptide array and confirmed by sequencing and Western blot, single lab, no functional consequence of tubulin interaction established","pmids":["17530867"],"is_preprint":false},{"year":2007,"finding":"ATP hydrolysis cycle of P-gp (ABCB1): ATP binds at the interface of the two nucleotide-binding domains (NBDs), inducing formation of a closed NBD dimer; this dimerization and subsequent ATP hydrolysis power drug transport. The power-stroke is provided specifically upon formation of the pre-hydrolysis transition-like (E·S) state during ATP hydrolysis, not simply from ATP binding alone.","method":"Mutational analysis of NBDs combined with biochemical ATPase assays; reviewed in conjunction with structural studies of isolated NBDs","journal":"Molecular cancer therapeutics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic model supported by mutagenesis and biochemical work from multiple studies reviewed, but this is a review paper synthesizing prior experimental work rather than a single primary experiment","pmids":["17237262"],"is_preprint":false},{"year":2011,"finding":"Sildenafil inhibits ABCB1 transport function by stimulating ABCB1 ATPase activity and competitively inhibiting photolabeling of ABCB1 with [125I]-iodoarylazidoprazosin (IAAP), indicating it binds within the drug-binding pocket of ABCB1's transmembrane domain. Sildenafil reverses ABCB1-mediated resistance and increases intracellular accumulation of ABCB1 substrates (paclitaxel). Sildenafil does not affect ABCC1 function.","method":"ATPase activity assay; [125I]-IAAP photolabeling/competition assay; intracellular drug accumulation assay; cytotoxicity reversal assay; homology modeling","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — ATPase assay plus competitive photolabeling of drug-binding site are direct mechanistic assays; single lab but multiple orthogonal biochemical methods","pmids":["21402712"],"is_preprint":false},{"year":2015,"finding":"ABCB1 (P-gp) exhibits structural flexibility evidenced by multiple X-ray crystal structures of mouse P-gp in inward-facing conformations with different degrees of domain separation, in absence of nucleotide and with bound inhibitors. Site-directed mutagenesis reveals multiple transport-active binding sites for single substrates (primary and secondary sites), with a large common drug-binding pocket with overlapping sites, accounting for polyspecificity.","method":"X-ray crystallography of mouse P-gp; site-directed mutagenesis; biochemical and biophysical studies; molecular modeling and SAR analysis","journal":"Advances in cancer research","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structures combined with mutagenesis and biochemical studies provide multiple independent lines of evidence for binding site architecture and conformational flexibility","pmids":["25640267"],"is_preprint":false},{"year":2015,"finding":"Cell surface P-gp (ABCB1) is degraded primarily via the lysosomal pathway. Bafilomycin A1 (vacuolar H+ ATPase inhibitor) increased the half-life of P-gp from ~27 h to ~36 h, while proteasomal inhibitors alone had no effect. Combined lysosomal and proteasomal inhibition further extended half-life to 39–50 h. Intracellular P-gp co-localizes with lysosomal marker LAMP1, confirming lysosomal compartment as the primary degradation site.","method":"Cell surface biotinylation; flow cytometry; Western blotting; pharmacological inhibitor treatment (BafA1, MG132, MG115, lactacystin); immunofluorescence co-localization with LAMP1","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple pharmacological inhibitors with quantitative half-life measurements plus co-localization with lysosomal marker, single lab with several orthogonal methods","pmids":["26057472"],"is_preprint":false},{"year":2018,"finding":"ABCB1/P-gp and LRP1 mediate concerted transcytosis of amyloid-beta (Aβ) across brain endothelial cells at the blood-brain barrier. PICALM (Alzheimer's risk factor) physically associates with both ABCB1/P-gp and LRP1 (shown by immunoprecipitation and co-immunostaining), serving as a functional link guiding both proteins through the brain endothelium. Dual inhibition of ABCB1 and LRP1 demonstrates their cooperative requirement for rapid Aβ clearance.","method":"Immunoprecipitation; co-immunostaining; dual pharmacological inhibition of ABCB1 and LRP1; functional Aβ transport assay","journal":"Brain, behavior, and immunity","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal immunoprecipitation plus functional dual inhibition, single lab with two orthogonal approaches","pmids":["30041013"],"is_preprint":false},{"year":2018,"finding":"ABCB1/P-gp plays a functional role in extravillous trophoblast (EVT) invasion and migration beyond its transporter role. siRNA silencing of ABCB1 in HTR8/SVneo EVT-like cells dramatically reduces invasion and migration while increasing tube formation, fusion, and induction of syncytiotrophoblast differentiation markers (hCG, ERVW-1, GJA1), demonstrating P-gp maintains trophoblast lineage identity and suppresses terminal differentiation.","method":"siRNA knockdown; invasion and migration assays; tube formation assay; trophoblast fusion assay; gene expression analysis of differentiation markers in EVT and CT explants","journal":"Journal of cellular and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with defined cellular phenotypes in multiple trophoblast models, single lab with multiple orthogonal readouts","pmids":["30256530"],"is_preprint":false},{"year":2019,"finding":"ABCB1 mediates efficient drug efflux in bat cells, and higher ABCB1 expression underlies bats' superior resistance to DNA damage from genotoxic drugs. Inhibition of ABCB1 with inhibitors triggers accumulation of doxorubicin, increased DNA damage, and cell death in bat cells. ABCB1 expression is conserved at higher levels across multiple bat species compared to human and mouse cells.","method":"Pharmacological ABCB1 inhibition; intracellular drug accumulation assay; DNA damage assay; cell viability assay; Western blot; comparison across multiple bat species and cell lines","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — pharmacological inhibition with multiple functional readouts replicated across multiple bat species and cell types","pmids":["31249297"],"is_preprint":false},{"year":2019,"finding":"Gut microbiota downregulates ABCB1 expression in the small intestine via bacterial metabolites that act on the Constitutive Androstane Receptor (CAR), reducing ABCB1 transcription. This modulation of ABCB1 expression by the microbiome directly affects tacrolimus pharmacokinetics: antibiotic-treated mice with lower microbial load had higher ABCB1 expression and 33% lower tacrolimus blood exposure. Functional ABCB1 inhibition with zosuquidar in vivo confirmed ABCB1 as the mediator.","method":"Antibiotic depletion model; germ-free mouse conventionalization; in vivo ABCB1 functional inhibition with zosuquidar; pharmacokinetic analysis; transcriptome analysis; in vitro polar bacterial metabolite experiments; CAR identification","journal":"Microbiome","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple in vivo models (antibiotic depletion, germ-free conventionalization) plus definitive pharmacological ABCB1 inhibition, mechanistic pathway to CAR identified, multiple orthogonal approaches","pmids":["37408070"],"is_preprint":false},{"year":2019,"finding":"P-gp/ABCB1 plays a significant role in restricting brain distribution of norbuprenorphine but has only a minor impact on fetal exposure. In Abcb1a/1b knockout mice, maternal brain-to-plasma AUC ratio for norbuprenorphine increased ~30-fold compared to wild-type, while fetal-to-maternal plasma AUC ratio was relatively unchanged. The differential effect is attributed to higher P-gp protein abundance in brain (BBB) versus placenta (blood-placental barrier), quantified by LC-MS/MS proteomics.","method":"Abcb1a/1b and Abcb1a/1b/Abcg2 knockout mouse models; pharmacokinetic tissue distribution analysis; LC-MS/MS protein quantification in tissues","journal":"Pharmacological research","confidence":"High","confidence_rationale":"Tier 2 / Strong — knockout mouse pharmacokinetics with quantitative protein abundance data providing mechanistic explanation; multiple knockout genotypes tested","pmids":["28111265"],"is_preprint":false},{"year":2009,"finding":"P-gp (Abcb1/ABCB1) restricts oral (re)uptake of etoposide and mediates its excretion across the gut wall, established using Abcb1a/1b knockout mice. This was distinct from hepatobiliary excretion, which was almost entirely dependent on Abcc2. In vivo etoposide pharmacokinetics in knockout mouse combinations delineated the separate contributions of P-gp, Abcc2, and Abcc3 to etoposide disposition.","method":"Abcb1a/1b(-/-), Abcc2(-/-), Abcc3(-/-) single and combination knockout mice; in vivo pharmacokinetic analysis of etoposide and etoposide glucuronide","journal":"Clinical cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis via multiple knockout combinations definitively assigns P-gp's role in intestinal etoposide transport, replicated with combination knockouts","pmids":["20028753"],"is_preprint":false},{"year":2020,"finding":"ABCB1 employs an ATP-dependent 'twist-and-squeeze' mechanism to export hydrophobic substrates. High-resolution X-ray crystal structures of pre- and post-transport states reveal that an aromatic hydrophobic network at the top of the inner cavity is critical for conformational change triggered by substrate. ATP binding (not hydrolysis) drives a twisting motion of the whole protein, squeezing out substrate directly to the extracellular space. FRET analyses in living cells confirmed this conformational mechanism.","method":"High-resolution X-ray crystallography of pre- and post-transport states; FRET analyses in living cells","journal":"FEBS letters","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structures of two functional states plus FRET in living cells, providing structural and cell-based validation of the transport mechanism","pmids":["33275773"],"is_preprint":false},{"year":2022,"finding":"CDK6 and PI3K (110α/110β) form a signaling axis that synergistically regulates ABCB1 expression. CRISPR/Cas9 knockout of CDK6 in KB-C2 cells led to downregulation of PI3K 110α/110β, KRAS, and MAPK10, and dramatically reduced ABCB1 expression reversing ABCB1-mediated MDR. PI3K 110α/110β deficiency in turn downregulated CDK6. CDK6-induced changes in ABCB1 levels involve alternative splicing of premature ABCB1 mRNA, with 10 common skipped exon events identified.","method":"CRISPR/Cas9 knockout of CDK6 or CDK4; Western blot; RT-PCR; transcriptome analysis; flow cytometry; in vivo xenograft models; alternative splicing analysis","journal":"Molecular cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPR knockout with transcriptome analysis and in vivo validation, single lab, multiple orthogonal readouts","pmids":["35459184"],"is_preprint":false},{"year":2022,"finding":"USP7 is a deubiquitinating enzyme for ABCB1 that directly interacts with ABCB1 and stabilizes the protein, thereby promoting chemoresistance. USP7 overexpression increased ABCB1-dependent chemoresistance in TNBC cells, while USP7 knockdown reduced chemoresistance. The interaction was demonstrated by co-immunoprecipitation, and USP7 inhibitor induced apoptosis and suppressed metastasis in chemoresistant TNBC.","method":"Co-immunoprecipitation; USP7 overexpression and siRNA knockdown; cytotoxicity assays; USP7 pharmacological inhibitor; apoptosis and migration assays","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP demonstrates direct interaction, functional consequence validated by both genetic knockdown and pharmacological inhibition, single lab","pmids":["36291159"],"is_preprint":false},{"year":2019,"finding":"TGF-β1 upregulates ABCB1 (P-gp) expression in hepatocellular carcinoma cells through the SMAD4/HOTAIR/miR-145 axis: TGF-β1 induces HOTAIR lncRNA in a SMAD4-dependent manner; HOTAIR suppresses miR-145 through EZH2; miR-145 directly suppresses ABCB1 expression by binding to the 3'-UTR of ABCB1 mRNA.","method":"SMAD4 siRNA knockdown; HOTAIR siRNA knockdown; EZH2 siRNA knockdown; miR-145 functional assays; 3'-UTR luciferase reporter assay (implied); Western blot; qPCR","journal":"Biopharmaceutics & drug disposition","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — pathway dissected by sequential siRNA knockdowns, single lab; 3'-UTR binding by miR-145 to ABCB1 established by reporter assay","pmids":["30698830"],"is_preprint":false},{"year":2013,"finding":"Methadone is an inhibitor (not substrate) of wild-type human P-gp via non-competitive kinetics (IC50 ~2.17 µM), and also stimulates P-gp ATPase activity. Variant P-gp (1236T-2677T-3435T and 1236T-2677A-3435T haplotypes) show reduced inhibition potency and uncompetitive kinetics, demonstrating that ABCB1 haplotype variants alter the mechanism of P-gp/drug interaction.","method":"Stable transfection of Flp-In-293 cells with various P-gp genotypes; rhodamine 123 efflux assay; calcein-AM uptake assay; ATPase assay; kinetic analysis","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional ATPase and transport assays in cells stably expressing defined genotypes with kinetic analysis, single lab, multiple assay methods","pmids":["23527191"],"is_preprint":false},{"year":2016,"finding":"P-gp (ABCB1) activity in primary CD4+ T cells reduces intracellular accumulation of raltegravir: CD4+P-gphigh cells accumulated 38.4% less raltegravir than P-gplow cells, and this was reversed by P-gp inhibitor XR9051. In vitro HIV-1 infection increased P-gp mRNA and activity in CD4+ T cells, and P-gphigh CD4+ T cells sustained higher HIV-1 replication. HIV-1 viral load positively correlated with P-gp activity in memory CD4+ T cell subsets.","method":"[3H]raltegravir accumulation assay; calcein-AM efflux assay; P-gp inhibitor XR9051 pharmacological blockade; flow cytometry; qRT-PCR; primary CD4+ T cells from HIV-infected patients","journal":"The Journal of antimicrobial chemotherapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct drug accumulation measured with radiolabeled compound plus pharmacological inhibition in primary cells, single lab with multiple experimental approaches","pmids":["27334660"],"is_preprint":false},{"year":2019,"finding":"Human P-gp (ABCB1) can be purified at large scale from High-Five insect cells using baculovirus expression; the purified protein, when reconstituted into proteoliposomes and nanodiscs, exhibits basal and substrate/inhibitor-modulated ATPase activity, confirming the reconstituted protein is functionally active. An E556Q/E1201Q Walker B mutant defective in ATP hydrolysis was also purified, enabling mechanistic studies.","method":"Baculovirus expression in insect cells; IMAC and SEC purification; reconstitution into proteoliposomes and nanodiscs; ATPase activity assay; Walker B mutagenesis","journal":"Protein expression and purification","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstitution of purified protein with functional ATPase validation and ATP hydrolysis-deficient mutant, single lab, multiple reconstitution systems","pmids":["30851394"],"is_preprint":false},{"year":2001,"finding":"Expression of P-glycoprotein (P-170/ABCB1) in CEM lymphoblastoid cells sensitizes them to mitochondria-mediated apoptosis. TNF-alpha and staurosporine (mitochondrion-mediated proapoptotic stimuli) were more effective at inducing cell death in P-170-expressing VBL100 cells than in wild-type cells, associated with mitochondrial membrane hyperpolarization in VBL100 cells under steady-state conditions. In contrast, Fas/CD95 and etoposide-induced apoptosis occurred preferentially in wild-type cells, indicating P-gp expression shifts the apoptotic pathway from plasma membrane-associated (Type I) to mitochondria-associated (Type II) cell death.","method":"Comparison of P-170-expressing VBL100 vs wild-type CEM cells; apoptosis assays with TNF-alpha, staurosporine, Fas/CD95, etoposide; mitochondrial membrane potential measurements","journal":"The Biochemical journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — defined functional consequence of P-gp expression on apoptotic pathway choice with multiple stimuli and mitochondrial membrane characterization, single lab","pmids":["11311119"],"is_preprint":false}],"current_model":"ABCB1/P-glycoprotein is an ATP-hydrolyzing efflux pump (ABC transporter) that uses ATP binding to drive a 'twist-and-squeeze' conformational change—transitioning from an inward-facing to an outward-facing state—to export structurally diverse hydrophobic substrates (drugs, xenobiotics, lipids, steroids, amyloid-beta) across membranes at tissue barriers (gut, liver canaliculi, blood-brain barrier, placenta); its two nucleotide-binding domains form a closed dimer powered by the pre-hydrolysis transition state, its large polyspecific drug-binding pocket accommodates multiple substrates simultaneously, it is degraded via the lysosomal pathway, it is stabilized post-translationally by the deubiquitinase USP7, its transcription is regulated by nuclear receptors (PXR, CAR) responding to bacterial metabolites and xenobiotics, and beyond drug transport it maintains trophoblast lineage identity and modulates apoptotic pathway choice toward mitochondria-mediated cell death."},"narrative":{"mechanistic_narrative":"ABCB1 (P-glycoprotein/Gp170) is an ATP-dependent efflux pump that drives vectorial export of structurally diverse hydrophobic substrates across membranes at tissue barriers [PMID:2568355, PMID:1347031, PMID:15640379]. It couples ATP binding and hydrolysis at a closed dimer of its two nucleotide-binding domains to a 'twist-and-squeeze' conformational cycle, transitioning between inward- and outward-facing states to expel substrate to the extracellular space, as resolved by crystal structures of pre- and post-transport states and confirmed by FRET in living cells [PMID:17237262, PMID:33275773]; a large, polyspecific drug-binding pocket within the transmembrane domains contains overlapping primary and secondary sites that accommodate multiple substrates, accounting for its broad specificity [PMID:25640267, PMID:21402712]. Functionally, ABCB1 establishes barrier and protective roles at the liver canaliculus, intestinal brush border, placental syncytiotrophoblast, and blood-brain barrier, where it restricts oral uptake and brain penetration of xenobiotics and drugs [PMID:2568355, PMID:1347031, PMID:15640379, PMID:20028753, PMID:28111265], and it cooperates with LRP1 (via PICALM) in transcytotic clearance of amyloid-beta across brain endothelium [PMID:30041013]. Its abundance is set transcriptionally by nuclear receptors responding to microbial metabolites—gut bacteria downregulate ABCB1 through the Constitutive Androstane Receptor—and by a CDK6/PI3K signaling axis and a TGF-β1/SMAD4/HOTAIR/miR-145 pathway acting on ABCB1 mRNA [PMID:37408070, PMID:35459184, PMID:30698830], while at the protein level it is degraded through the lysosomal pathway and stabilized by the deubiquitinase USP7 [PMID:26057472, PMID:36291159]. Beyond transport, ABCB1 maintains extravillous trophoblast invasiveness and suppresses syncytiotrophoblast differentiation, and its expression shifts apoptotic pathway choice toward mitochondria-mediated cell death [PMID:30256530, PMID:11311119].","teleology":[{"year":1989,"claim":"Established that ABCB1/Gp170 is itself an ATP-driven primary active transporter rather than a passive component, by demonstrating energized, vectorial drug efflux in defined membrane vesicles.","evidence":"ATP-dependent daunomycin transport in rat liver canalicular inside-out vesicles with non-hydrolyzable analogue and inhibitor controls","pmids":["2568355"],"confidence":"High","gaps":["Did not resolve the structural basis of transport","Substrate range and binding-site architecture not defined"]},{"year":1992,"claim":"Extended the efflux function to an epithelial barrier role, showing ABCB1 acts as an intestinal gate against hydrophobic xenobiotics.","evidence":"ATP-dependent transport in rat intestinal brush border vesicles plus everted intestine directional transport of rhodamine 123","pmids":["1347031"],"confidence":"High","gaps":["Quantitative contribution to oral bioavailability in vivo not addressed","Did not identify regulatory inputs"]},{"year":2001,"claim":"Revealed a non-transport function: ABCB1 expression reprograms apoptotic pathway choice toward mitochondria-mediated death.","evidence":"Comparison of P-170-expressing VBL100 vs wild-type CEM cells across multiple proapoptotic stimuli with mitochondrial membrane potential measurement","pmids":["11311119"],"confidence":"Medium","gaps":["Molecular mechanism linking P-gp to mitochondrial polarization unknown","Single cell-line pair"]},{"year":2005,"claim":"Confirmed functional ABCB1 efflux activity at the placental syncytiotrophoblast, supporting a fetal-protective barrier.","evidence":"ATP-dependent, osmotically sensitive, verapamil-inhibitable vinblastine uptake in human placental vesicles with immunohistochemistry","pmids":["15640379"],"confidence":"High","gaps":["Relative contribution vs other placental transporters not quantified"]},{"year":2006,"claim":"Mapped ABCB1 to luminal and abluminal BBB endothelial membranes plus biosynthetic and trafficking compartments, framing it as a regulator of brain drug distribution.","evidence":"Immunogold electron microscopy in situ in rat and human brain","pmids":["16801529"],"confidence":"Medium","gaps":["Functional significance of bilateral and intracellular pools not tested","Single lab"]},{"year":2007,"claim":"Defined the ATP hydrolysis cycle as the power source, identifying the closed NBD dimer and pre-hydrolysis transition state as the power-stroke.","evidence":"NBD mutagenesis and ATPase assays synthesized with structural studies (review)","pmids":["17237262"],"confidence":"Medium","gaps":["Review synthesis rather than single primary experiment","Coupling to substrate movement not directly visualized here"]},{"year":2007,"claim":"Identified a direct physical interaction between the ABCB1 linker domain and alpha/beta-tubulin, linking the pump to the cytoskeleton.","evidence":"Overlapping hexapeptide binding, protein purification, N-terminal sequencing and anti-tubulin Western blot","pmids":["17530867"],"confidence":"Medium","gaps":["No functional consequence of tubulin binding established","In vitro peptide interaction only"]},{"year":2009,"claim":"Used genetic epistasis to assign ABCB1 a specific role in intestinal etoposide efflux, distinct from hepatobiliary excretion handled by Abcc2.","evidence":"Single and combination Abcb1a/1b, Abcc2, Abcc3 knockout mouse pharmacokinetics","pmids":["20028753"],"confidence":"High","gaps":["Human translation of transporter division of labor not addressed"]},{"year":2011,"claim":"Demonstrated that inhibitors such as sildenafil act within the drug-binding pocket to reverse ABCB1-mediated resistance, validating the transmembrane pocket as a pharmacological target.","evidence":"ATPase stimulation, competitive [125I]-IAAP photolabeling, drug accumulation and cytotoxicity reversal assays","pmids":["21402712"],"confidence":"High","gaps":["Exact residues contacted not resolved","Specificity over other ABC transporters only partially tested"]},{"year":2013,"claim":"Showed that ABCB1 coding haplotypes alter the kinetic mechanism of drug interaction, establishing that genotype reshapes pump pharmacology.","evidence":"Stable expression of defined P-gp genotypes with rhodamine/calcein efflux, ATPase and kinetic analysis using methadone","pmids":["23527191"],"confidence":"Medium","gaps":["Clinical pharmacokinetic consequences not measured","Limited to specific haplotypes/substrate"]},{"year":2015,"claim":"Provided structural and mutational evidence for conformational flexibility and a single large polyspecific binding pocket with overlapping sites, explaining substrate promiscuity.","evidence":"Multiple inward-facing mouse P-gp crystal structures with site-directed mutagenesis and SAR (review/primary structural work)","pmids":["25640267"],"confidence":"High","gaps":["Outward-facing transition not captured in these structures","Mouse rather than human protein"]},{"year":2015,"claim":"Identified the lysosome as the primary route of ABCB1 turnover, defining a post-translational determinant of pump abundance.","evidence":"Cell surface biotinylation half-life measurements with lysosomal/proteasomal inhibitors and LAMP1 co-localization","pmids":["26057472"],"confidence":"High","gaps":["Ubiquitin/trafficking signals routing P-gp to lysosomes not defined here"]},{"year":2018,"claim":"Placed ABCB1 in a cooperative amyloid-beta clearance pathway with LRP1, physically linked by PICALM at the BBB.","evidence":"Immunoprecipitation, co-immunostaining and dual ABCB1/LRP1 inhibition with Aβ transport assay","pmids":["30041013"],"confidence":"Medium","gaps":["Direct vs indirect nature of the ABCB1-PICALM-LRP1 association unresolved","Single lab"]},{"year":2018,"claim":"Revealed a transport-independent developmental role: ABCB1 maintains extravillous trophoblast invasiveness and suppresses syncytiotrophoblast differentiation.","evidence":"siRNA knockdown in HTR8/SVneo with invasion, migration, fusion, tube formation and differentiation-marker assays","pmids":["30256530"],"confidence":"Medium","gaps":["Molecular effector downstream of P-gp not identified","Cell-line model"]},{"year":2019,"claim":"Dissected transcriptional and mRNA-level control of ABCB1, identifying microbiota/CAR, CDK6/PI3K, and TGF-β1/SMAD4/HOTAIR/miR-145 inputs.","evidence":"In vivo microbiota depletion/conventionalization with CAR identification; CRISPR CDK6 knockout with splicing/transcriptome analysis; sequential siRNA dissection with 3'-UTR reporter","pmids":["37408070","35459184","30698830"],"confidence":"Medium","gaps":["Direct receptor binding to ABCB1 promoter not all resolved","Cross-talk among these pathways unknown"]},{"year":2019,"claim":"Quantitatively linked tissue-specific ABCB1 protein abundance to differential barrier function, with strong brain but minor placental restriction of norbuprenorphine.","evidence":"Abcb1a/1b knockout mouse tissue pharmacokinetics with LC-MS/MS protein quantification","pmids":["28111265"],"confidence":"High","gaps":["Human placental relevance not directly tested"]},{"year":2019,"claim":"Established a recombinant purification and reconstitution platform, confirming the isolated protein is a functional ATPase and enabling hydrolysis-deficient mutant studies.","evidence":"Baculovirus expression, IMAC/SEC purification, proteoliposome/nanodisc reconstitution with ATPase assays and E556Q/E1201Q Walker B mutant","pmids":["30851394"],"confidence":"High","gaps":["Does not by itself define a transport mechanism"]},{"year":2019,"claim":"Connected ABCB1 efflux to cellular drug/genotoxin resistance and to retention of antiretroviral and chemotherapeutic agents in physiological cell types.","evidence":"Pharmacological inhibition with drug accumulation, DNA damage and viability readouts in bat cells; raltegravir accumulation in primary CD4+ T cells with XR9051","pmids":["31249297","27334660"],"confidence":"Medium","gaps":["Mechanism of elevated ABCB1 expression in these contexts only partly defined"]},{"year":2020,"claim":"Resolved the transport mechanism at near-atomic detail, showing ATP binding drives a whole-protein twisting that squeezes substrate directly to the extracellular space.","evidence":"High-resolution crystal structures of pre- and post-transport states with FRET in living cells","pmids":["33275773"],"confidence":"High","gaps":["Precise role of hydrolysis vs binding across substrates still debated","Dynamics of substrate loading not fully captured"]},{"year":2022,"claim":"Identified USP7 as a deubiquitinase that directly binds and stabilizes ABCB1, defining a druggable axis controlling pump levels and chemoresistance.","evidence":"Co-immunoprecipitation with USP7 overexpression/knockdown and pharmacological inhibition in TNBC cells","pmids":["36291159"],"confidence":"Medium","gaps":["Specific ubiquitin sites on ABCB1 not mapped","Single lab, Co-IP-based interaction"]},{"year":null,"claim":"How ABCB1's transport-independent activities (trophoblast identity, apoptotic pathway choice, cytoskeletal linkage) mechanistically arise and integrate with its canonical efflux function remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No molecular effector connecting P-gp to mitochondrial apoptosis or trophoblast differentiation identified","Functional role of tubulin binding untested","Integration of multiple regulatory pathways controlling ABCB1 abundance not unified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140657","term_label":"ATP-dependent activity","supporting_discovery_ids":[0,1,2,5,15,21]},{"term_id":"GO:0005215","term_label":"transporter activity","supporting_discovery_ids":[0,1,2,14,13,20]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[5,6,21]},{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[4]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,1,2,3,8]},{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[8]},{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[3]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[3]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[3]}],"pathway":[{"term_id":"R-HSA-382551","term_label":"Transport of small molecules","supporting_discovery_ids":[0,1,2,14,13]},{"term_id":"R-HSA-9748784","term_label":"Drug ADME","supporting_discovery_ids":[14,13,19,20]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[9,11,16,17]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[22]}],"complexes":[],"partners":["LRP1","PICALM","USP7","TUBA","TUBB"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P08183","full_name":"ATP-dependent translocase ABCB1","aliases":["ATP-binding cassette sub-family B member 1","Multidrug resistance protein 1","P-glycoprotein 1","Phospholipid transporter ABCB1"],"length_aa":1280,"mass_kda":141.5,"function":"Translocates drugs and phospholipids across the membrane (PubMed:2897240, PubMed:35970996, PubMed:8898203, PubMed:9038218, PubMed:35507548). Catalyzes the flop of phospholipids from the cytoplasmic to the exoplasmic leaflet of the apical membrane. Participates mainly to the flop of phosphatidylcholine, phosphatidylethanolamine, beta-D-glucosylceramides and sphingomyelins (PubMed:8898203). Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells (PubMed:2897240, PubMed:35970996, PubMed:9038218)","subcellular_location":"Cell membrane; Apical cell membrane; Cytoplasm","url":"https://www.uniprot.org/uniprotkb/P08183/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ABCB1","classification":"Not Classified","n_dependent_lines":5,"n_total_lines":1208,"dependency_fraction":0.0041390728476821195},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"CANX","stoichiometry":0.2},{"gene":"RAB11A","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/ABCB1","total_profiled":1310},"omim":[{"mim_id":"620950","title":"ENCEPHALOPATHY, ACUTE TRANSIENT; ENPAT","url":"https://www.omim.org/entry/620950"},{"mim_id":"619612","title":"B-CELL RECEPTOR-ASSOCIATED PROTEIN 29; BCAP29","url":"https://www.omim.org/entry/619612"},{"mim_id":"615902","title":"PROTEIN PHOSPHATASE 2, REGULATORY SUBUNIT B-DOUBLE PRIME, GAMMA; PPP2R3C","url":"https://www.omim.org/entry/615902"},{"mim_id":"614914","title":"MICRO RNA 298; MIR298","url":"https://www.omim.org/entry/614914"},{"mim_id":"614546","title":"EFAVIRENZ, POOR METABOLISM OF","url":"https://www.omim.org/entry/614546"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"adrenal gland","ntpm":96.1},{"tissue":"intestine","ntpm":66.6}],"url":"https://www.proteinatlas.org/search/ABCB1"},"hgnc":{"alias_symbol":["P-gp","CD243","GP170","ABC20","p-170","PGY1"],"prev_symbol":["PGY1","MDR1","CLCS"]},"alphafold":{"accession":"P08183","domains":[{"cath_id":"1.20.1560.10","chopping":"212-325_684-851_972-1021","consensus_level":"medium","plddt":87.4578,"start":212,"end":1021},{"cath_id":"3.40.50.300","chopping":"391-631","consensus_level":"medium","plddt":89.7837,"start":391,"end":631},{"cath_id":"3.40.50.300","chopping":"1034-1274","consensus_level":"medium","plddt":89.7515,"start":1034,"end":1274}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P08183","model_url":"https://alphafold.ebi.ac.uk/files/AF-P08183-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P08183-F1-predicted_aligned_error_v6.png","plddt_mean":84.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ABCB1","jax_strain_url":"https://www.jax.org/strain/search?query=ABCB1"},"sequence":{"accession":"P08183","fasta_url":"https://rest.uniprot.org/uniprotkb/P08183.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P08183/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P08183"}},"corpus_meta":[{"pmid":"22257057","id":"PMC_22257057","title":"Three decades of P-gp inhibitors: skimming through several generations and scaffolds.","date":"2012","source":"Current medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22257057","citation_count":419,"is_preprint":false},{"pmid":"9214671","id":"PMC_9214671","title":"Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance.","date":"1997","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/9214671","citation_count":353,"is_preprint":false},{"pmid":"2568355","id":"PMC_2568355","title":"The function of Gp170, the multidrug resistance gene product, in rat liver canalicular membrane vesicles.","date":"1989","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2568355","citation_count":312,"is_preprint":false},{"pmid":"17898703","id":"PMC_17898703","title":"Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief.","date":"2007","source":"Clinical pharmacology and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/17898703","citation_count":245,"is_preprint":false},{"pmid":"16143395","id":"PMC_16143395","title":"Expression of the multidrug resistance P-glycoprotein, (ABCB1 glycoprotein) in the human placenta decreases with advancing gestation.","date":"2005","source":"Placenta","url":"https://pubmed.ncbi.nlm.nih.gov/16143395","citation_count":175,"is_preprint":false},{"pmid":"16352426","id":"PMC_16352426","title":"The power of the pump: mechanisms of action of P-glycoprotein (ABCB1).","date":"2005","source":"European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/16352426","citation_count":169,"is_preprint":false},{"pmid":"16801529","id":"PMC_16801529","title":"In situ localization of P-glycoprotein (ABCB1) in human and rat brain.","date":"2006","source":"The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society","url":"https://pubmed.ncbi.nlm.nih.gov/16801529","citation_count":166,"is_preprint":false},{"pmid":"19165709","id":"PMC_19165709","title":"ABC transporter (P-gp/ABCB1, MRP1/ABCC1, BCRP/ABCG2) expression in the developing human CNS.","date":"2009","source":"Neuropediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/19165709","citation_count":146,"is_preprint":false},{"pmid":"15228162","id":"PMC_15228162","title":"Clinical aspects of the MDR1 (ABCB1) gene polymorphism.","date":"2004","source":"Therapeutic drug monitoring","url":"https://pubmed.ncbi.nlm.nih.gov/15228162","citation_count":143,"is_preprint":false},{"pmid":"21402712","id":"PMC_21402712","title":"Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.","date":"2011","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/21402712","citation_count":143,"is_preprint":false},{"pmid":"1347031","id":"PMC_1347031","title":"The function of Gp170, the multidrug-resistance gene product, in the brush border of rat intestinal mucosa.","date":"1992","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/1347031","citation_count":141,"is_preprint":false},{"pmid":"15217301","id":"PMC_15217301","title":"The MDR1 (ABCB1) gene polymorphism and its clinical implications.","date":"2004","source":"Clinical pharmacokinetics","url":"https://pubmed.ncbi.nlm.nih.gov/15217301","citation_count":124,"is_preprint":false},{"pmid":"17237262","id":"PMC_17237262","title":"About a switch: how P-glycoprotein (ABCB1) harnesses the energy of ATP binding and hydrolysis to do mechanical work.","date":"2007","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/17237262","citation_count":121,"is_preprint":false},{"pmid":"30041013","id":"PMC_30041013","title":"The concerted amyloid-beta clearance of LRP1 and ABCB1/P-gp across the blood-brain barrier is linked by PICALM.","date":"2018","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/30041013","citation_count":117,"is_preprint":false},{"pmid":"25640267","id":"PMC_25640267","title":"Molecular basis of the polyspecificity of P-glycoprotein (ABCB1): recent biochemical and structural studies.","date":"2015","source":"Advances in cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/25640267","citation_count":113,"is_preprint":false},{"pmid":"18288958","id":"PMC_18288958","title":"Genuine functions of P-glycoprotein (ABCB1).","date":"2008","source":"Current drug metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/18288958","citation_count":111,"is_preprint":false},{"pmid":"8792427","id":"PMC_8792427","title":"Age-dependent expression of P-glycoprotein gp170 in Caco-2 cell monolayers.","date":"1996","source":"Pharmaceutical research","url":"https://pubmed.ncbi.nlm.nih.gov/8792427","citation_count":111,"is_preprint":false},{"pmid":"17259950","id":"PMC_17259950","title":"ABCB1 pharmacogenetics: progress, pitfalls, and promise.","date":"2007","source":"Clinical pharmacology and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/17259950","citation_count":105,"is_preprint":false},{"pmid":"30010462","id":"PMC_30010462","title":"An update on expression and function of P-gp/ABCB1 and BCRP/ABCG2 in the placenta and fetus.","date":"2018","source":"Expert opinion on drug metabolism & toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/30010462","citation_count":96,"is_preprint":false},{"pmid":"17954525","id":"PMC_17954525","title":"Localization of P-gp (Abcb1) and Mrp2 (Abcc2) in freshly isolated rat hepatocytes.","date":"2007","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/17954525","citation_count":85,"is_preprint":false},{"pmid":"17593551","id":"PMC_17593551","title":"Oxycodone induces overexpression of P-glycoprotein (ABCB1) and affects paclitaxel's tissue distribution in Sprague Dawley rats.","date":"2007","source":"Journal of pharmaceutical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/17593551","citation_count":83,"is_preprint":false},{"pmid":"19442042","id":"PMC_19442042","title":"Recent advances in the development of P-gp inhibitors.","date":"2009","source":"Anti-cancer agents in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19442042","citation_count":82,"is_preprint":false},{"pmid":"20028753","id":"PMC_20028753","title":"P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide.","date":"2009","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/20028753","citation_count":77,"is_preprint":false},{"pmid":"24107928","id":"PMC_24107928","title":"Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib.","date":"2013","source":"Clinical pharmacology and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/24107928","citation_count":74,"is_preprint":false},{"pmid":"15247630","id":"PMC_15247630","title":"Modulation of multidrug resistance P-glycoprotein 1 (ABCB1) expression in human heart by hereditary polymorphisms.","date":"2004","source":"Pharmacogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/15247630","citation_count":72,"is_preprint":false},{"pmid":"20555295","id":"PMC_20555295","title":"ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression.","date":"2010","source":"Pharmacogenetics and genomics","url":"https://pubmed.ncbi.nlm.nih.gov/20555295","citation_count":71,"is_preprint":false},{"pmid":"15328029","id":"PMC_15328029","title":"Expression of P-glycoprotein (ABCB1) and Mrp1 (ABCC1) in adult rat brain: focus on astrocytes.","date":"2004","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/15328029","citation_count":70,"is_preprint":false},{"pmid":"19552816","id":"PMC_19552816","title":"Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma.","date":"2009","source":"BMC urology","url":"https://pubmed.ncbi.nlm.nih.gov/19552816","citation_count":69,"is_preprint":false},{"pmid":"16842213","id":"PMC_16842213","title":"MDR1/P-glycoprotein (ABCB1) as target for RNA interference-mediated reversal of multidrug resistance.","date":"2006","source":"Current drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/16842213","citation_count":68,"is_preprint":false},{"pmid":"37686513","id":"PMC_37686513","title":"Genetics of ABCB1 in Cancer.","date":"2023","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/37686513","citation_count":66,"is_preprint":false},{"pmid":"25915534","id":"PMC_25915534","title":"Trametinib modulates cancer multidrug resistance by targeting ABCB1 transporter.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25915534","citation_count":63,"is_preprint":false},{"pmid":"18058211","id":"PMC_18058211","title":"Genomics and the mechanism of P-glycoprotein (ABCB1).","date":"2007","source":"Journal of bioenergetics and biomembranes","url":"https://pubmed.ncbi.nlm.nih.gov/18058211","citation_count":62,"is_preprint":false},{"pmid":"19465099","id":"PMC_19465099","title":"Permeation of astilbin and taxifolin in Caco-2 cell and their effects on the P-gp.","date":"2009","source":"International journal of pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/19465099","citation_count":61,"is_preprint":false},{"pmid":"15640379","id":"PMC_15640379","title":"Expression and function of ABCB1 and ABCG2 in human placental tissue.","date":"2005","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/15640379","citation_count":60,"is_preprint":false},{"pmid":"24058883","id":"PMC_24058883","title":"Cannabidiol changes P-gp and BCRP expression in trophoblast cell lines.","date":"2013","source":"PeerJ","url":"https://pubmed.ncbi.nlm.nih.gov/24058883","citation_count":55,"is_preprint":false},{"pmid":"31078601","id":"PMC_31078601","title":"Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells.","date":"2019","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31078601","citation_count":54,"is_preprint":false},{"pmid":"29317984","id":"PMC_29317984","title":"P-glycoprotein (ABCB1) and Oxidative Stress: Focus on Alzheimer's Disease.","date":"2017","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/29317984","citation_count":50,"is_preprint":false},{"pmid":"26197160","id":"PMC_26197160","title":"Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.","date":"2015","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26197160","citation_count":50,"is_preprint":false},{"pmid":"35459184","id":"PMC_35459184","title":"CDK6-PI3K signaling axis is an efficient target for attenuating ABCB1/P-gp mediated multi-drug resistance (MDR) in cancer cells.","date":"2022","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35459184","citation_count":50,"is_preprint":false},{"pmid":"24703092","id":"PMC_24703092","title":"Influence of UGT2B7, OPRM1 and ABCB1 gene polymorphisms on postoperative morphine consumption.","date":"2014","source":"Basic & clinical pharmacology & toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/24703092","citation_count":50,"is_preprint":false},{"pmid":"17933685","id":"PMC_17933685","title":"Drug-drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1) II. Clinical aspects.","date":"2007","source":"Drug discovery today","url":"https://pubmed.ncbi.nlm.nih.gov/17933685","citation_count":50,"is_preprint":false},{"pmid":"27262378","id":"PMC_27262378","title":"Ferulic acid reverses ABCB1-mediated paclitaxel resistance in MDR cell lines.","date":"2016","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/27262378","citation_count":48,"is_preprint":false},{"pmid":"37408070","id":"PMC_37408070","title":"Gut microbiome modulates tacrolimus pharmacokinetics through the transcriptional regulation of ABCB1.","date":"2023","source":"Microbiome","url":"https://pubmed.ncbi.nlm.nih.gov/37408070","citation_count":47,"is_preprint":false},{"pmid":"22464980","id":"PMC_22464980","title":"Oral and inhaled corticosteroids: differences in P-glycoprotein (ABCB1) mediated efflux.","date":"2012","source":"Toxicology and applied pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/22464980","citation_count":45,"is_preprint":false},{"pmid":"19415305","id":"PMC_19415305","title":"ABCB1 gene polymorphisms and haplotype analysis in colorectal cancer.","date":"2009","source":"International journal of colorectal disease","url":"https://pubmed.ncbi.nlm.nih.gov/19415305","citation_count":45,"is_preprint":false},{"pmid":"32517082","id":"PMC_32517082","title":"Homology Modeling of the Human P-glycoprotein (ABCB1) and Insights into Ligand Binding through Molecular Docking Studies.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32517082","citation_count":45,"is_preprint":false},{"pmid":"30698830","id":"PMC_30698830","title":"TGF-β1 elevates P-gp and BCRP in hepatocellular carcinoma through HOTAIR/miR-145 axis.","date":"2019","source":"Biopharmaceutics & drug disposition","url":"https://pubmed.ncbi.nlm.nih.gov/30698830","citation_count":44,"is_preprint":false},{"pmid":"33275773","id":"PMC_33275773","title":"ABCB1/MDR1/P-gp employs an ATP-dependent twist-and-squeeze mechanism to export hydrophobic drugs.","date":"2020","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/33275773","citation_count":42,"is_preprint":false},{"pmid":"29071751","id":"PMC_29071751","title":"PXR mediated induction of CYP3A4, CYP1A2, and P-gp by Mitragyna speciosa and its alkaloids.","date":"2017","source":"Phytotherapy research : PTR","url":"https://pubmed.ncbi.nlm.nih.gov/29071751","citation_count":42,"is_preprint":false},{"pmid":"30789308","id":"PMC_30789308","title":"Polymorphisms in CYP1A2, CYP2C9 and ABCB1 affect agomelatine pharmacokinetics.","date":"2019","source":"Journal of psychopharmacology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/30789308","citation_count":41,"is_preprint":false},{"pmid":"31249297","id":"PMC_31249297","title":"ABCB1 protects bat cells from DNA damage induced by genotoxic compounds.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31249297","citation_count":41,"is_preprint":false},{"pmid":"23469685","id":"PMC_23469685","title":"ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics.","date":"2013","source":"Die Pharmazie","url":"https://pubmed.ncbi.nlm.nih.gov/23469685","citation_count":41,"is_preprint":false},{"pmid":"30280663","id":"PMC_30280663","title":"Drug-Drug Interactions of P-gp Substrates Unrelated to CYP Metabolism.","date":"2019","source":"Current drug metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/30280663","citation_count":40,"is_preprint":false},{"pmid":"33543229","id":"PMC_33543229","title":"Role of ABCB1 in mediating chemoresistance of triple-negative breast cancers.","date":"2021","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/33543229","citation_count":40,"is_preprint":false},{"pmid":"30256530","id":"PMC_30256530","title":"P-Glycoprotein (P-gp)/ABCB1 plays a functional role in extravillous trophoblast (EVT) invasion and is decreased in the pre-eclamptic placenta.","date":"2018","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30256530","citation_count":40,"is_preprint":false},{"pmid":"18922637","id":"PMC_18922637","title":"Canine ABCB1 and macrocyclic lactones: heartworm prevention and pharmacogenetics.","date":"2008","source":"Veterinary parasitology","url":"https://pubmed.ncbi.nlm.nih.gov/18922637","citation_count":38,"is_preprint":false},{"pmid":"25640268","id":"PMC_25640268","title":"Lipid regulation of the ABCB1 and ABCG2 multidrug transporters.","date":"2015","source":"Advances in cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/25640268","citation_count":38,"is_preprint":false},{"pmid":"16674925","id":"PMC_16674925","title":"Effects of capsaicin on P-gp function and expression in Caco-2 cells.","date":"2006","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16674925","citation_count":37,"is_preprint":false},{"pmid":"27897269","id":"PMC_27897269","title":"An integrated pharmacokinetic/pharmacogenomic analysis of ABCB1 and SLCO1B1 polymorphisms on edoxaban exposure.","date":"2016","source":"The pharmacogenomics journal","url":"https://pubmed.ncbi.nlm.nih.gov/27897269","citation_count":37,"is_preprint":false},{"pmid":"27918249","id":"PMC_27918249","title":"ABCB1 genotyping in the treatment of depression.","date":"2016","source":"Pharmacogenomics","url":"https://pubmed.ncbi.nlm.nih.gov/27918249","citation_count":36,"is_preprint":false},{"pmid":"28303028","id":"PMC_28303028","title":"Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivo.","date":"2017","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28303028","citation_count":36,"is_preprint":false},{"pmid":"23527191","id":"PMC_23527191","title":"Functional impact of ABCB1 variants on interactions between P-glycoprotein and methadone.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23527191","citation_count":36,"is_preprint":false},{"pmid":"27588398","id":"PMC_27588398","title":"ABCB1 and ABCC11 confer resistance to eribulin in breast cancer cell lines.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27588398","citation_count":34,"is_preprint":false},{"pmid":"19545213","id":"PMC_19545213","title":"Dietary regulation of P-gp function and expression.","date":"2009","source":"Expert opinion on drug metabolism & toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/19545213","citation_count":33,"is_preprint":false},{"pmid":"20664232","id":"PMC_20664232","title":"Antidepressants and ABCB1 gene C3435T functional polymorphism: a naturalistic study.","date":"2010","source":"Neuropsychobiology","url":"https://pubmed.ncbi.nlm.nih.gov/20664232","citation_count":32,"is_preprint":false},{"pmid":"17933684","id":"PMC_17933684","title":"Drug-drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1) I. Preclinical aspects.","date":"2007","source":"Drug discovery today","url":"https://pubmed.ncbi.nlm.nih.gov/17933684","citation_count":32,"is_preprint":false},{"pmid":"21366702","id":"PMC_21366702","title":"P-glycoprotein (ABCB1) expression in human skin is mainly restricted to dermal components.","date":"2011","source":"Experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/21366702","citation_count":31,"is_preprint":false},{"pmid":"26057472","id":"PMC_26057472","title":"Revealing the fate of cell surface human P-glycoprotein (ABCB1): The lysosomal degradation pathway.","date":"2015","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/26057472","citation_count":30,"is_preprint":false},{"pmid":"32186270","id":"PMC_32186270","title":"Expression of P-gp in Glioblastoma: What we can Learn from Brain Development.","date":"2020","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/32186270","citation_count":29,"is_preprint":false},{"pmid":"28101689","id":"PMC_28101689","title":"Gene Therapeutic Approaches to Overcome ABCB1-Mediated Drug Resistance.","date":"2016","source":"Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28101689","citation_count":29,"is_preprint":false},{"pmid":"17530867","id":"PMC_17530867","title":"The P-glycoprotein (ABCB1) linker domain encodes high-affinity binding sequences to alpha- and beta-tubulins.","date":"2007","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17530867","citation_count":29,"is_preprint":false},{"pmid":"20138191","id":"PMC_20138191","title":"Emerging new technologies in Pharmacogenomics: rapid SNP detection, molecular dynamic simulation, and QSAR analysis methods to validate clinically important genetic variants of human ABC Transporter ABCB1 (P-gp/MDR1).","date":"2010","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/20138191","citation_count":29,"is_preprint":false},{"pmid":"25487678","id":"PMC_25487678","title":"ABCB1 (MDR1) predicts remission on P-gp substrates in chronic depression.","date":"2014","source":"The pharmacogenomics journal","url":"https://pubmed.ncbi.nlm.nih.gov/25487678","citation_count":28,"is_preprint":false},{"pmid":"32903706","id":"PMC_32903706","title":"Antimicrobial Peptide Reverses ABCB1-Mediated Chemotherapeutic Drug Resistance.","date":"2020","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32903706","citation_count":28,"is_preprint":false},{"pmid":"31871496","id":"PMC_31871496","title":"ABCB1 Polymorphisms and Drug-Resistant Epilepsy in a Tunisian Population.","date":"2019","source":"Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/31871496","citation_count":28,"is_preprint":false},{"pmid":"28189906","id":"PMC_28189906","title":"Dregamine and tabernaemontanine derivatives as ABCB1 modulators on resistant cancer cells.","date":"2017","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28189906","citation_count":28,"is_preprint":false},{"pmid":"36291159","id":"PMC_36291159","title":"USP7 Induces Chemoresistance in Triple-Negative Breast Cancer via Deubiquitination and Stabilization of ABCB1.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/36291159","citation_count":27,"is_preprint":false},{"pmid":"19290795","id":"PMC_19290795","title":"CYP3A5 and ABCB1 genes and hypertension.","date":"2009","source":"Pharmacogenomics","url":"https://pubmed.ncbi.nlm.nih.gov/19290795","citation_count":26,"is_preprint":false},{"pmid":"28111265","id":"PMC_28111265","title":"P-gp/ABCB1 exerts differential impacts on brain and fetal exposure to norbuprenorphine.","date":"2017","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/28111265","citation_count":26,"is_preprint":false},{"pmid":"14613723","id":"PMC_14613723","title":"Potential roles of P-gp and calcium channels in loperamide and diphenoxylate transport.","date":"2003","source":"Toxicology and applied pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/14613723","citation_count":26,"is_preprint":false},{"pmid":"28534954","id":"PMC_28534954","title":"Uncaria alkaloids reverse ABCB1-mediated cancer multidrug resistance.","date":"2017","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28534954","citation_count":26,"is_preprint":false},{"pmid":"24980806","id":"PMC_24980806","title":"Cyclosporin A affects the bioavailability of ginkgolic acids via inhibition of P-gp and BCRP.","date":"2014","source":"European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V","url":"https://pubmed.ncbi.nlm.nih.gov/24980806","citation_count":26,"is_preprint":false},{"pmid":"34347777","id":"PMC_34347777","title":"Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer.","date":"2021","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/34347777","citation_count":25,"is_preprint":false},{"pmid":"25660379","id":"PMC_25660379","title":"Identification of a nonsense mutation in feline ABCB1.","date":"2015","source":"Journal of veterinary pharmacology and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/25660379","citation_count":25,"is_preprint":false},{"pmid":"25437111","id":"PMC_25437111","title":"Cargoing P-gp inhibitors via nanoparticle sensitizes tumor cells against doxorubicin.","date":"2014","source":"International journal of pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/25437111","citation_count":25,"is_preprint":false},{"pmid":"36499131","id":"PMC_36499131","title":"Recent Advances on P-Glycoprotein (ABCB1) Transporter Modelling with In Silico Methods.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36499131","citation_count":23,"is_preprint":false},{"pmid":"18075465","id":"PMC_18075465","title":"Promoter polymorphisms and allelic imbalance in ABCB1 expression.","date":"2007","source":"Pharmacogenetics and genomics","url":"https://pubmed.ncbi.nlm.nih.gov/18075465","citation_count":23,"is_preprint":false},{"pmid":"11311119","id":"PMC_11311119","title":"Expression of P-170 glycoprotein sensitizes lymphoblastoid CEM cells to mitochondria-mediated apoptosis.","date":"2001","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/11311119","citation_count":23,"is_preprint":false},{"pmid":"25430046","id":"PMC_25430046","title":"Impact of common ABCB1 polymorphism on pharmacokinetics and pharmacodynamics of clopidogrel and its metabolites.","date":"2014","source":"Journal of clinical pharmacy and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/25430046","citation_count":23,"is_preprint":false},{"pmid":"32164732","id":"PMC_32164732","title":"Reversal of ABCB1-related multidrug resistance by ERK5-IN-1.","date":"2020","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/32164732","citation_count":22,"is_preprint":false},{"pmid":"28546766","id":"PMC_28546766","title":"ABCB1 genetic variants in leukemias: current insights into treatment outcomes.","date":"2017","source":"Pharmacogenomics and personalized medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28546766","citation_count":22,"is_preprint":false},{"pmid":"26681082","id":"PMC_26681082","title":"OPRM1 and ABCB1 polymorphisms and their effect on postoperative pain relief with piritramide.","date":"2015","source":"Physiological research","url":"https://pubmed.ncbi.nlm.nih.gov/26681082","citation_count":22,"is_preprint":false},{"pmid":"33921129","id":"PMC_33921129","title":"Dual Inhibition of P-gp and BCRP Improves Oral Topotecan Bioavailability in Rodents.","date":"2021","source":"Pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/33921129","citation_count":21,"is_preprint":false},{"pmid":"27334660","id":"PMC_27334660","title":"P-glycoprotein (ABCB1) activity decreases raltegravir disposition in primary CD4+P-gphigh cells and correlates with HIV-1 viral load.","date":"2016","source":"The Journal of antimicrobial chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/27334660","citation_count":21,"is_preprint":false},{"pmid":"30851394","id":"PMC_30851394","title":"Large-scale purification of functional human P-glycoprotein (ABCB1).","date":"2019","source":"Protein expression and purification","url":"https://pubmed.ncbi.nlm.nih.gov/30851394","citation_count":20,"is_preprint":false},{"pmid":"25976226","id":"PMC_25976226","title":"Evaluation of dual P-gp-BCRP inhibitors as nanoparticle formulation.","date":"2015","source":"European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/25976226","citation_count":20,"is_preprint":false},{"pmid":"21887726","id":"PMC_21887726","title":"Is there evidence to claim or deny association between variants of the multidrug resistance gene (MDR1 or ABCB1) and inflammatory bowel disease?","date":"2011","source":"Inflammatory bowel diseases","url":"https://pubmed.ncbi.nlm.nih.gov/21887726","citation_count":20,"is_preprint":false},{"pmid":"30760665","id":"PMC_30760665","title":"CCL20 Promotes Ovarian Cancer Chemotherapy Resistance by Regulating ABCB1 Expression.","date":"2019","source":"Cell structure and function","url":"https://pubmed.ncbi.nlm.nih.gov/30760665","citation_count":19,"is_preprint":false},{"pmid":"20738225","id":"PMC_20738225","title":"ABCB1 and ABCG2 expression in the placenta and fetus: an interspecies comparison.","date":"2010","source":"Expert opinion on drug metabolism & toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/20738225","citation_count":18,"is_preprint":false},{"pmid":"21887256","id":"PMC_21887256","title":"BPR1K653, a novel Aurora kinase inhibitor, exhibits potent anti-proliferative activity in MDR1 (P-gp170)-mediated multidrug-resistant cancer cells.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21887256","citation_count":18,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52481,"output_tokens":6914,"usd":0.130577,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16103,"output_tokens":5545,"usd":0.10957,"stage2_stop_reason":"end_turn"},"total_usd":0.240147,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1989,\n      \"finding\": \"Gp170 (ABCB1/P-gp) functions as an ATP-dependent efflux pump in rat liver canalicular membrane vesicles, mediating unidirectional, temperature-dependent, osmotically sensitive, and saturable transport of daunomycin. ATP hydrolysis (not non-hydrolyzable analogues) is required, and transport is inhibited by cytotoxic drugs (vinblastine, vincristine, adriamycin) and verapamil/quinidine. Only inside-out vesicles (cytoplasmic face outward) support transport, establishing vectorial drug efflux into bile.\",\n      \"method\": \"ATP-dependent transport assay in canalicular membrane vesicles; antibody-induced affinity density perturbation to separate inside-out from right-side-out vesicles; inhibitor studies\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstituted transport assay with multiple orthogonal controls (non-hydrolyzable ATP analogues, inhibitors, osmotic sensitivity, inside-out vs right-side-out vesicles), replicated concept across labs\",\n      \"pmids\": [\"2568355\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"Gp170 (ABCB1) in rat small intestinal brush border membrane vesicles (but not basolateral) functions as an ATP-dependent efflux pump transporting daunomycin from inside to outside. Non-hydrolyzable ATP analogues are ineffective. Everted intestine preparations confirm Gp170-mediated serosal-to-mucosal transport of rhodamine 123, inhibitable by Gp170 inhibitors, establishing P-gp as an intestinal barrier against hydrophobic xenobiotics.\",\n      \"method\": \"ATP-dependent transport assay in brush border membrane vesicles; everted intestine transport assay; inhibitor studies; Western blot with anti-Gp170 antibody\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstituted transport in native membrane vesicles with multiple controls, directional transport confirmed by two complementary experimental systems\",\n      \"pmids\": [\"1347031\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"ABCB1/P-gp in human placenta is functionally active as an ATP-dependent efflux transporter: ATP-dependent uptake of [3H]vinblastine in placental vesicles is osmotically sensitive (indicating intravesicular accumulation) and inhibited by verapamil. The protein is expressed at high levels and localized to the syncytiotrophoblast, consistent with a fetal-protective barrier role.\",\n      \"method\": \"ATP-dependent vesicle transport assay with [3H]vinblastine; verapamil inhibition; Western blotting; immunohistochemistry\",\n      \"journal\": \"Drug metabolism and disposition\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstituted transport assay with osmotic sensitivity and pharmacological inhibition controls, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"15640379\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"In human and rat brain, P-gp (ABCB1) localizes to both luminal and abluminal membranes of capillary endothelial cells, as well as to adjacent pericytes and astrocytes. Subcellularly, P-gp is distributed in caveolae, cytoplasmic vesicles, Golgi complex, rough ER, and nuclear envelope, indicating sites of synthesis, glycosylation, and membrane trafficking. Bilateral membrane localization suggests P-gp regulates drug transport processes across the entire BBB.\",\n      \"method\": \"Immunogold cytochemistry at electron microscope level in situ in rat and human brain tissue\",\n      \"journal\": \"The journal of histochemistry and cytochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct subcellular localization by immunogold EM, single lab, two species examined\",\n      \"pmids\": [\"16801529\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"The linker domain of human ABCB1 (approximately 90 amino acid region connecting the two halves) contains sequences that directly bind alpha- and beta-tubulins. Three polypeptide sequences (LDS617-627, LDS657-676, LDS693-705) interact with a ~57 kDa protein identified by N-terminal sequencing and anti-tubulin Western blot as alpha- and beta-tubulin, establishing a direct protein-protein interaction between ABCB1 and cytoskeletal components.\",\n      \"method\": \"Overlapping hexapeptide binding assay; protein purification; N-terminal amino acid sequencing; Western blot with anti-tubulin monoclonal antibodies\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — direct binding demonstrated by peptide array and confirmed by sequencing and Western blot, single lab, no functional consequence of tubulin interaction established\",\n      \"pmids\": [\"17530867\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"ATP hydrolysis cycle of P-gp (ABCB1): ATP binds at the interface of the two nucleotide-binding domains (NBDs), inducing formation of a closed NBD dimer; this dimerization and subsequent ATP hydrolysis power drug transport. The power-stroke is provided specifically upon formation of the pre-hydrolysis transition-like (E·S) state during ATP hydrolysis, not simply from ATP binding alone.\",\n      \"method\": \"Mutational analysis of NBDs combined with biochemical ATPase assays; reviewed in conjunction with structural studies of isolated NBDs\",\n      \"journal\": \"Molecular cancer therapeutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic model supported by mutagenesis and biochemical work from multiple studies reviewed, but this is a review paper synthesizing prior experimental work rather than a single primary experiment\",\n      \"pmids\": [\"17237262\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Sildenafil inhibits ABCB1 transport function by stimulating ABCB1 ATPase activity and competitively inhibiting photolabeling of ABCB1 with [125I]-iodoarylazidoprazosin (IAAP), indicating it binds within the drug-binding pocket of ABCB1's transmembrane domain. Sildenafil reverses ABCB1-mediated resistance and increases intracellular accumulation of ABCB1 substrates (paclitaxel). Sildenafil does not affect ABCC1 function.\",\n      \"method\": \"ATPase activity assay; [125I]-IAAP photolabeling/competition assay; intracellular drug accumulation assay; cytotoxicity reversal assay; homology modeling\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — ATPase assay plus competitive photolabeling of drug-binding site are direct mechanistic assays; single lab but multiple orthogonal biochemical methods\",\n      \"pmids\": [\"21402712\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ABCB1 (P-gp) exhibits structural flexibility evidenced by multiple X-ray crystal structures of mouse P-gp in inward-facing conformations with different degrees of domain separation, in absence of nucleotide and with bound inhibitors. Site-directed mutagenesis reveals multiple transport-active binding sites for single substrates (primary and secondary sites), with a large common drug-binding pocket with overlapping sites, accounting for polyspecificity.\",\n      \"method\": \"X-ray crystallography of mouse P-gp; site-directed mutagenesis; biochemical and biophysical studies; molecular modeling and SAR analysis\",\n      \"journal\": \"Advances in cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structures combined with mutagenesis and biochemical studies provide multiple independent lines of evidence for binding site architecture and conformational flexibility\",\n      \"pmids\": [\"25640267\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Cell surface P-gp (ABCB1) is degraded primarily via the lysosomal pathway. Bafilomycin A1 (vacuolar H+ ATPase inhibitor) increased the half-life of P-gp from ~27 h to ~36 h, while proteasomal inhibitors alone had no effect. Combined lysosomal and proteasomal inhibition further extended half-life to 39–50 h. Intracellular P-gp co-localizes with lysosomal marker LAMP1, confirming lysosomal compartment as the primary degradation site.\",\n      \"method\": \"Cell surface biotinylation; flow cytometry; Western blotting; pharmacological inhibitor treatment (BafA1, MG132, MG115, lactacystin); immunofluorescence co-localization with LAMP1\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple pharmacological inhibitors with quantitative half-life measurements plus co-localization with lysosomal marker, single lab with several orthogonal methods\",\n      \"pmids\": [\"26057472\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ABCB1/P-gp and LRP1 mediate concerted transcytosis of amyloid-beta (Aβ) across brain endothelial cells at the blood-brain barrier. PICALM (Alzheimer's risk factor) physically associates with both ABCB1/P-gp and LRP1 (shown by immunoprecipitation and co-immunostaining), serving as a functional link guiding both proteins through the brain endothelium. Dual inhibition of ABCB1 and LRP1 demonstrates their cooperative requirement for rapid Aβ clearance.\",\n      \"method\": \"Immunoprecipitation; co-immunostaining; dual pharmacological inhibition of ABCB1 and LRP1; functional Aβ transport assay\",\n      \"journal\": \"Brain, behavior, and immunity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal immunoprecipitation plus functional dual inhibition, single lab with two orthogonal approaches\",\n      \"pmids\": [\"30041013\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ABCB1/P-gp plays a functional role in extravillous trophoblast (EVT) invasion and migration beyond its transporter role. siRNA silencing of ABCB1 in HTR8/SVneo EVT-like cells dramatically reduces invasion and migration while increasing tube formation, fusion, and induction of syncytiotrophoblast differentiation markers (hCG, ERVW-1, GJA1), demonstrating P-gp maintains trophoblast lineage identity and suppresses terminal differentiation.\",\n      \"method\": \"siRNA knockdown; invasion and migration assays; tube formation assay; trophoblast fusion assay; gene expression analysis of differentiation markers in EVT and CT explants\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with defined cellular phenotypes in multiple trophoblast models, single lab with multiple orthogonal readouts\",\n      \"pmids\": [\"30256530\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ABCB1 mediates efficient drug efflux in bat cells, and higher ABCB1 expression underlies bats' superior resistance to DNA damage from genotoxic drugs. Inhibition of ABCB1 with inhibitors triggers accumulation of doxorubicin, increased DNA damage, and cell death in bat cells. ABCB1 expression is conserved at higher levels across multiple bat species compared to human and mouse cells.\",\n      \"method\": \"Pharmacological ABCB1 inhibition; intracellular drug accumulation assay; DNA damage assay; cell viability assay; Western blot; comparison across multiple bat species and cell lines\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — pharmacological inhibition with multiple functional readouts replicated across multiple bat species and cell types\",\n      \"pmids\": [\"31249297\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Gut microbiota downregulates ABCB1 expression in the small intestine via bacterial metabolites that act on the Constitutive Androstane Receptor (CAR), reducing ABCB1 transcription. This modulation of ABCB1 expression by the microbiome directly affects tacrolimus pharmacokinetics: antibiotic-treated mice with lower microbial load had higher ABCB1 expression and 33% lower tacrolimus blood exposure. Functional ABCB1 inhibition with zosuquidar in vivo confirmed ABCB1 as the mediator.\",\n      \"method\": \"Antibiotic depletion model; germ-free mouse conventionalization; in vivo ABCB1 functional inhibition with zosuquidar; pharmacokinetic analysis; transcriptome analysis; in vitro polar bacterial metabolite experiments; CAR identification\",\n      \"journal\": \"Microbiome\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple in vivo models (antibiotic depletion, germ-free conventionalization) plus definitive pharmacological ABCB1 inhibition, mechanistic pathway to CAR identified, multiple orthogonal approaches\",\n      \"pmids\": [\"37408070\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"P-gp/ABCB1 plays a significant role in restricting brain distribution of norbuprenorphine but has only a minor impact on fetal exposure. In Abcb1a/1b knockout mice, maternal brain-to-plasma AUC ratio for norbuprenorphine increased ~30-fold compared to wild-type, while fetal-to-maternal plasma AUC ratio was relatively unchanged. The differential effect is attributed to higher P-gp protein abundance in brain (BBB) versus placenta (blood-placental barrier), quantified by LC-MS/MS proteomics.\",\n      \"method\": \"Abcb1a/1b and Abcb1a/1b/Abcg2 knockout mouse models; pharmacokinetic tissue distribution analysis; LC-MS/MS protein quantification in tissues\",\n      \"journal\": \"Pharmacological research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — knockout mouse pharmacokinetics with quantitative protein abundance data providing mechanistic explanation; multiple knockout genotypes tested\",\n      \"pmids\": [\"28111265\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"P-gp (Abcb1/ABCB1) restricts oral (re)uptake of etoposide and mediates its excretion across the gut wall, established using Abcb1a/1b knockout mice. This was distinct from hepatobiliary excretion, which was almost entirely dependent on Abcc2. In vivo etoposide pharmacokinetics in knockout mouse combinations delineated the separate contributions of P-gp, Abcc2, and Abcc3 to etoposide disposition.\",\n      \"method\": \"Abcb1a/1b(-/-), Abcc2(-/-), Abcc3(-/-) single and combination knockout mice; in vivo pharmacokinetic analysis of etoposide and etoposide glucuronide\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis via multiple knockout combinations definitively assigns P-gp's role in intestinal etoposide transport, replicated with combination knockouts\",\n      \"pmids\": [\"20028753\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ABCB1 employs an ATP-dependent 'twist-and-squeeze' mechanism to export hydrophobic substrates. High-resolution X-ray crystal structures of pre- and post-transport states reveal that an aromatic hydrophobic network at the top of the inner cavity is critical for conformational change triggered by substrate. ATP binding (not hydrolysis) drives a twisting motion of the whole protein, squeezing out substrate directly to the extracellular space. FRET analyses in living cells confirmed this conformational mechanism.\",\n      \"method\": \"High-resolution X-ray crystallography of pre- and post-transport states; FRET analyses in living cells\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structures of two functional states plus FRET in living cells, providing structural and cell-based validation of the transport mechanism\",\n      \"pmids\": [\"33275773\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CDK6 and PI3K (110α/110β) form a signaling axis that synergistically regulates ABCB1 expression. CRISPR/Cas9 knockout of CDK6 in KB-C2 cells led to downregulation of PI3K 110α/110β, KRAS, and MAPK10, and dramatically reduced ABCB1 expression reversing ABCB1-mediated MDR. PI3K 110α/110β deficiency in turn downregulated CDK6. CDK6-induced changes in ABCB1 levels involve alternative splicing of premature ABCB1 mRNA, with 10 common skipped exon events identified.\",\n      \"method\": \"CRISPR/Cas9 knockout of CDK6 or CDK4; Western blot; RT-PCR; transcriptome analysis; flow cytometry; in vivo xenograft models; alternative splicing analysis\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR knockout with transcriptome analysis and in vivo validation, single lab, multiple orthogonal readouts\",\n      \"pmids\": [\"35459184\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"USP7 is a deubiquitinating enzyme for ABCB1 that directly interacts with ABCB1 and stabilizes the protein, thereby promoting chemoresistance. USP7 overexpression increased ABCB1-dependent chemoresistance in TNBC cells, while USP7 knockdown reduced chemoresistance. The interaction was demonstrated by co-immunoprecipitation, and USP7 inhibitor induced apoptosis and suppressed metastasis in chemoresistant TNBC.\",\n      \"method\": \"Co-immunoprecipitation; USP7 overexpression and siRNA knockdown; cytotoxicity assays; USP7 pharmacological inhibitor; apoptosis and migration assays\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP demonstrates direct interaction, functional consequence validated by both genetic knockdown and pharmacological inhibition, single lab\",\n      \"pmids\": [\"36291159\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TGF-β1 upregulates ABCB1 (P-gp) expression in hepatocellular carcinoma cells through the SMAD4/HOTAIR/miR-145 axis: TGF-β1 induces HOTAIR lncRNA in a SMAD4-dependent manner; HOTAIR suppresses miR-145 through EZH2; miR-145 directly suppresses ABCB1 expression by binding to the 3'-UTR of ABCB1 mRNA.\",\n      \"method\": \"SMAD4 siRNA knockdown; HOTAIR siRNA knockdown; EZH2 siRNA knockdown; miR-145 functional assays; 3'-UTR luciferase reporter assay (implied); Western blot; qPCR\",\n      \"journal\": \"Biopharmaceutics & drug disposition\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — pathway dissected by sequential siRNA knockdowns, single lab; 3'-UTR binding by miR-145 to ABCB1 established by reporter assay\",\n      \"pmids\": [\"30698830\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Methadone is an inhibitor (not substrate) of wild-type human P-gp via non-competitive kinetics (IC50 ~2.17 µM), and also stimulates P-gp ATPase activity. Variant P-gp (1236T-2677T-3435T and 1236T-2677A-3435T haplotypes) show reduced inhibition potency and uncompetitive kinetics, demonstrating that ABCB1 haplotype variants alter the mechanism of P-gp/drug interaction.\",\n      \"method\": \"Stable transfection of Flp-In-293 cells with various P-gp genotypes; rhodamine 123 efflux assay; calcein-AM uptake assay; ATPase assay; kinetic analysis\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional ATPase and transport assays in cells stably expressing defined genotypes with kinetic analysis, single lab, multiple assay methods\",\n      \"pmids\": [\"23527191\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"P-gp (ABCB1) activity in primary CD4+ T cells reduces intracellular accumulation of raltegravir: CD4+P-gphigh cells accumulated 38.4% less raltegravir than P-gplow cells, and this was reversed by P-gp inhibitor XR9051. In vitro HIV-1 infection increased P-gp mRNA and activity in CD4+ T cells, and P-gphigh CD4+ T cells sustained higher HIV-1 replication. HIV-1 viral load positively correlated with P-gp activity in memory CD4+ T cell subsets.\",\n      \"method\": \"[3H]raltegravir accumulation assay; calcein-AM efflux assay; P-gp inhibitor XR9051 pharmacological blockade; flow cytometry; qRT-PCR; primary CD4+ T cells from HIV-infected patients\",\n      \"journal\": \"The Journal of antimicrobial chemotherapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct drug accumulation measured with radiolabeled compound plus pharmacological inhibition in primary cells, single lab with multiple experimental approaches\",\n      \"pmids\": [\"27334660\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Human P-gp (ABCB1) can be purified at large scale from High-Five insect cells using baculovirus expression; the purified protein, when reconstituted into proteoliposomes and nanodiscs, exhibits basal and substrate/inhibitor-modulated ATPase activity, confirming the reconstituted protein is functionally active. An E556Q/E1201Q Walker B mutant defective in ATP hydrolysis was also purified, enabling mechanistic studies.\",\n      \"method\": \"Baculovirus expression in insect cells; IMAC and SEC purification; reconstitution into proteoliposomes and nanodiscs; ATPase activity assay; Walker B mutagenesis\",\n      \"journal\": \"Protein expression and purification\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstitution of purified protein with functional ATPase validation and ATP hydrolysis-deficient mutant, single lab, multiple reconstitution systems\",\n      \"pmids\": [\"30851394\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Expression of P-glycoprotein (P-170/ABCB1) in CEM lymphoblastoid cells sensitizes them to mitochondria-mediated apoptosis. TNF-alpha and staurosporine (mitochondrion-mediated proapoptotic stimuli) were more effective at inducing cell death in P-170-expressing VBL100 cells than in wild-type cells, associated with mitochondrial membrane hyperpolarization in VBL100 cells under steady-state conditions. In contrast, Fas/CD95 and etoposide-induced apoptosis occurred preferentially in wild-type cells, indicating P-gp expression shifts the apoptotic pathway from plasma membrane-associated (Type I) to mitochondria-associated (Type II) cell death.\",\n      \"method\": \"Comparison of P-170-expressing VBL100 vs wild-type CEM cells; apoptosis assays with TNF-alpha, staurosporine, Fas/CD95, etoposide; mitochondrial membrane potential measurements\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — defined functional consequence of P-gp expression on apoptotic pathway choice with multiple stimuli and mitochondrial membrane characterization, single lab\",\n      \"pmids\": [\"11311119\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ABCB1/P-glycoprotein is an ATP-hydrolyzing efflux pump (ABC transporter) that uses ATP binding to drive a 'twist-and-squeeze' conformational change—transitioning from an inward-facing to an outward-facing state—to export structurally diverse hydrophobic substrates (drugs, xenobiotics, lipids, steroids, amyloid-beta) across membranes at tissue barriers (gut, liver canaliculi, blood-brain barrier, placenta); its two nucleotide-binding domains form a closed dimer powered by the pre-hydrolysis transition state, its large polyspecific drug-binding pocket accommodates multiple substrates simultaneously, it is degraded via the lysosomal pathway, it is stabilized post-translationally by the deubiquitinase USP7, its transcription is regulated by nuclear receptors (PXR, CAR) responding to bacterial metabolites and xenobiotics, and beyond drug transport it maintains trophoblast lineage identity and modulates apoptotic pathway choice toward mitochondria-mediated cell death.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ABCB1 (P-glycoprotein/Gp170) is an ATP-dependent efflux pump that drives vectorial export of structurally diverse hydrophobic substrates across membranes at tissue barriers [#0, #1, #2]. It couples ATP binding and hydrolysis at a closed dimer of its two nucleotide-binding domains to a 'twist-and-squeeze' conformational cycle, transitioning between inward- and outward-facing states to expel substrate to the extracellular space, as resolved by crystal structures of pre- and post-transport states and confirmed by FRET in living cells [#5, #15]; a large, polyspecific drug-binding pocket within the transmembrane domains contains overlapping primary and secondary sites that accommodate multiple substrates, accounting for its broad specificity [#7, #6]. Functionally, ABCB1 establishes barrier and protective roles at the liver canaliculus, intestinal brush border, placental syncytiotrophoblast, and blood-brain barrier, where it restricts oral uptake and brain penetration of xenobiotics and drugs [#0, #1, #2, #14, #13], and it cooperates with LRP1 (via PICALM) in transcytotic clearance of amyloid-beta across brain endothelium [#9]. Its abundance is set transcriptionally by nuclear receptors responding to microbial metabolites—gut bacteria downregulate ABCB1 through the Constitutive Androstane Receptor—and by a CDK6/PI3K signaling axis and a TGF-β1/SMAD4/HOTAIR/miR-145 pathway acting on ABCB1 mRNA [#12, #16, #18], while at the protein level it is degraded through the lysosomal pathway and stabilized by the deubiquitinase USP7 [#8, #17]. Beyond transport, ABCB1 maintains extravillous trophoblast invasiveness and suppresses syncytiotrophoblast differentiation, and its expression shifts apoptotic pathway choice toward mitochondria-mediated cell death [#10, #22].\",\n  \"teleology\": [\n    {\n      \"year\": 1989,\n      \"claim\": \"Established that ABCB1/Gp170 is itself an ATP-driven primary active transporter rather than a passive component, by demonstrating energized, vectorial drug efflux in defined membrane vesicles.\",\n      \"evidence\": \"ATP-dependent daunomycin transport in rat liver canalicular inside-out vesicles with non-hydrolyzable analogue and inhibitor controls\",\n      \"pmids\": [\"2568355\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve the structural basis of transport\", \"Substrate range and binding-site architecture not defined\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Extended the efflux function to an epithelial barrier role, showing ABCB1 acts as an intestinal gate against hydrophobic xenobiotics.\",\n      \"evidence\": \"ATP-dependent transport in rat intestinal brush border vesicles plus everted intestine directional transport of rhodamine 123\",\n      \"pmids\": [\"1347031\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative contribution to oral bioavailability in vivo not addressed\", \"Did not identify regulatory inputs\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Revealed a non-transport function: ABCB1 expression reprograms apoptotic pathway choice toward mitochondria-mediated death.\",\n      \"evidence\": \"Comparison of P-170-expressing VBL100 vs wild-type CEM cells across multiple proapoptotic stimuli with mitochondrial membrane potential measurement\",\n      \"pmids\": [\"11311119\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular mechanism linking P-gp to mitochondrial polarization unknown\", \"Single cell-line pair\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Confirmed functional ABCB1 efflux activity at the placental syncytiotrophoblast, supporting a fetal-protective barrier.\",\n      \"evidence\": \"ATP-dependent, osmotically sensitive, verapamil-inhibitable vinblastine uptake in human placental vesicles with immunohistochemistry\",\n      \"pmids\": [\"15640379\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution vs other placental transporters not quantified\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Mapped ABCB1 to luminal and abluminal BBB endothelial membranes plus biosynthetic and trafficking compartments, framing it as a regulator of brain drug distribution.\",\n      \"evidence\": \"Immunogold electron microscopy in situ in rat and human brain\",\n      \"pmids\": [\"16801529\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional significance of bilateral and intracellular pools not tested\", \"Single lab\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Defined the ATP hydrolysis cycle as the power source, identifying the closed NBD dimer and pre-hydrolysis transition state as the power-stroke.\",\n      \"evidence\": \"NBD mutagenesis and ATPase assays synthesized with structural studies (review)\",\n      \"pmids\": [\"17237262\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Review synthesis rather than single primary experiment\", \"Coupling to substrate movement not directly visualized here\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identified a direct physical interaction between the ABCB1 linker domain and alpha/beta-tubulin, linking the pump to the cytoskeleton.\",\n      \"evidence\": \"Overlapping hexapeptide binding, protein purification, N-terminal sequencing and anti-tubulin Western blot\",\n      \"pmids\": [\"17530867\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No functional consequence of tubulin binding established\", \"In vitro peptide interaction only\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Used genetic epistasis to assign ABCB1 a specific role in intestinal etoposide efflux, distinct from hepatobiliary excretion handled by Abcc2.\",\n      \"evidence\": \"Single and combination Abcb1a/1b, Abcc2, Abcc3 knockout mouse pharmacokinetics\",\n      \"pmids\": [\"20028753\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Human translation of transporter division of labor not addressed\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Demonstrated that inhibitors such as sildenafil act within the drug-binding pocket to reverse ABCB1-mediated resistance, validating the transmembrane pocket as a pharmacological target.\",\n      \"evidence\": \"ATPase stimulation, competitive [125I]-IAAP photolabeling, drug accumulation and cytotoxicity reversal assays\",\n      \"pmids\": [\"21402712\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Exact residues contacted not resolved\", \"Specificity over other ABC transporters only partially tested\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Showed that ABCB1 coding haplotypes alter the kinetic mechanism of drug interaction, establishing that genotype reshapes pump pharmacology.\",\n      \"evidence\": \"Stable expression of defined P-gp genotypes with rhodamine/calcein efflux, ATPase and kinetic analysis using methadone\",\n      \"pmids\": [\"23527191\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Clinical pharmacokinetic consequences not measured\", \"Limited to specific haplotypes/substrate\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Provided structural and mutational evidence for conformational flexibility and a single large polyspecific binding pocket with overlapping sites, explaining substrate promiscuity.\",\n      \"evidence\": \"Multiple inward-facing mouse P-gp crystal structures with site-directed mutagenesis and SAR (review/primary structural work)\",\n      \"pmids\": [\"25640267\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Outward-facing transition not captured in these structures\", \"Mouse rather than human protein\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified the lysosome as the primary route of ABCB1 turnover, defining a post-translational determinant of pump abundance.\",\n      \"evidence\": \"Cell surface biotinylation half-life measurements with lysosomal/proteasomal inhibitors and LAMP1 co-localization\",\n      \"pmids\": [\"26057472\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ubiquitin/trafficking signals routing P-gp to lysosomes not defined here\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Placed ABCB1 in a cooperative amyloid-beta clearance pathway with LRP1, physically linked by PICALM at the BBB.\",\n      \"evidence\": \"Immunoprecipitation, co-immunostaining and dual ABCB1/LRP1 inhibition with Aβ transport assay\",\n      \"pmids\": [\"30041013\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect nature of the ABCB1-PICALM-LRP1 association unresolved\", \"Single lab\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Revealed a transport-independent developmental role: ABCB1 maintains extravillous trophoblast invasiveness and suppresses syncytiotrophoblast differentiation.\",\n      \"evidence\": \"siRNA knockdown in HTR8/SVneo with invasion, migration, fusion, tube formation and differentiation-marker assays\",\n      \"pmids\": [\"30256530\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular effector downstream of P-gp not identified\", \"Cell-line model\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Dissected transcriptional and mRNA-level control of ABCB1, identifying microbiota/CAR, CDK6/PI3K, and TGF-β1/SMAD4/HOTAIR/miR-145 inputs.\",\n      \"evidence\": \"In vivo microbiota depletion/conventionalization with CAR identification; CRISPR CDK6 knockout with splicing/transcriptome analysis; sequential siRNA dissection with 3'-UTR reporter\",\n      \"pmids\": [\"37408070\", \"35459184\", \"30698830\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct receptor binding to ABCB1 promoter not all resolved\", \"Cross-talk among these pathways unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Quantitatively linked tissue-specific ABCB1 protein abundance to differential barrier function, with strong brain but minor placental restriction of norbuprenorphine.\",\n      \"evidence\": \"Abcb1a/1b knockout mouse tissue pharmacokinetics with LC-MS/MS protein quantification\",\n      \"pmids\": [\"28111265\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Human placental relevance not directly tested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Established a recombinant purification and reconstitution platform, confirming the isolated protein is a functional ATPase and enabling hydrolysis-deficient mutant studies.\",\n      \"evidence\": \"Baculovirus expression, IMAC/SEC purification, proteoliposome/nanodisc reconstitution with ATPase assays and E556Q/E1201Q Walker B mutant\",\n      \"pmids\": [\"30851394\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not by itself define a transport mechanism\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Connected ABCB1 efflux to cellular drug/genotoxin resistance and to retention of antiretroviral and chemotherapeutic agents in physiological cell types.\",\n      \"evidence\": \"Pharmacological inhibition with drug accumulation, DNA damage and viability readouts in bat cells; raltegravir accumulation in primary CD4+ T cells with XR9051\",\n      \"pmids\": [\"31249297\", \"27334660\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of elevated ABCB1 expression in these contexts only partly defined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Resolved the transport mechanism at near-atomic detail, showing ATP binding drives a whole-protein twisting that squeezes substrate directly to the extracellular space.\",\n      \"evidence\": \"High-resolution crystal structures of pre- and post-transport states with FRET in living cells\",\n      \"pmids\": [\"33275773\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise role of hydrolysis vs binding across substrates still debated\", \"Dynamics of substrate loading not fully captured\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identified USP7 as a deubiquitinase that directly binds and stabilizes ABCB1, defining a druggable axis controlling pump levels and chemoresistance.\",\n      \"evidence\": \"Co-immunoprecipitation with USP7 overexpression/knockdown and pharmacological inhibition in TNBC cells\",\n      \"pmids\": [\"36291159\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific ubiquitin sites on ABCB1 not mapped\", \"Single lab, Co-IP-based interaction\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How ABCB1's transport-independent activities (trophoblast identity, apoptotic pathway choice, cytoskeletal linkage) mechanistically arise and integrate with its canonical efflux function remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No molecular effector connecting P-gp to mitochondrial apoptosis or trophoblast differentiation identified\", \"Functional role of tubulin binding untested\", \"Integration of multiple regulatory pathways controlling ABCB1 abundance not unified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [0, 1, 2, 5, 15, 21]},\n      {\"term_id\": \"GO:0005215\", \"supporting_discovery_ids\": [0, 1, 2, 14, 13, 20]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [5, 6, 21]},\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [4]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 1, 2, 3, 8]},\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [8]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [3]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [3]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [3]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-382551\", \"supporting_discovery_ids\": [0, 1, 2, 14, 13]},\n      {\"term_id\": \"R-HSA-9748784\", \"supporting_discovery_ids\": [14, 13, 19, 20]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [9, 11, 16, 17]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [22]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"LRP1\", \"PICALM\", \"USP7\", \"TUBA\", \"TUBB\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":5,"faith_pct":100.0}}